cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.21537646.v1
title: Role of traversing speed and axial load on the properties of friction stir welded dissimilar AA6101-T6 AND AA1350 aluminium alloys

description: Traditionally, AA6101-T6 and AA1350 aluminum alloys find prominent place in many industrial applications like electrical bus bar utilities for the sake of better conductivity. Friction Stir Welding is a non-traditional solid-state welding technique that was invented and developed by The Welding Institute. In this analysis, AA6101-T6 and AA1350 alloys have been put on experimentation with friction stir welding by varying axial load (5 kN to 9 kN) and traversing speed (60 mm/min to 120 mm/min). In order to examine the weld quality, properties such as tensile, wear and microstructural analyses have been carried out. From the results, it was observed that the weldment made with 7 kN axial load and 90 mm/min traversing speed exhibited better joint properties. Similarly, the weldment made with 5 kN axial load and 120 mm/min traversing speed exhibited poor joint properties. This has been attained due to the variations in heat input, metals softening and grain coarsening at weld nugget. Taguchi L<sub>9</sub> orthogonal array with ANOVA and Signal to Noise ratio have been adopted to understand the contribution of axial load and traversing speed on the properties of weldments. Results reveal that traversing speed is statistically significant on the properties of weldment, when compared to axial load.
DOI: 10.5281/zenodo.7401690
title: acanthurus_reversus_decontaminated_FSCR.fasta.gz

description: .
DOI: 10.5281/zenodo.7401689
title: acanthurus_reversus_decontaminated_FSCR.fasta.gz

description: .
DOI: 10.6073/pasta/399ee55d1885ff17ffe8616fd2193d4a
title: Lake Mendota Phosphorus Entrainment at North Temperate Lakes LTER 2005

description: This dataset contains total (TP) and soluble reactive phosphorus (SRP) data collected in Lake Mendota during the summer of 2005 between 6/28/2005 and 10/14/2005 as well as high-resolution temperature data for that same time period . The phosphorus data were taken at five different locations where buoys were deployed. The buoys were deployed with HOBO temperature data loggers attached at 2 - 4 m intervals. Similarly the phosphorus samples were collected at 2 - 4 m intervals throughout the water column. The position of the five buoys changed a few times during the summer in an effort to monitor circulation patterns due to different wind directions and speeds. Manuscript using this dataset: Kamarainen, A.M., H. Yuan, C. Wu, S.R. Carpenter. 2009. One-dimensional and three-dimensional approaches converge on similar estimates of phosphorus entrainment in Lake Mendota. Limnology and Oceanography Methods 7:553-567 Sampling frequency: Water temperature: generally 1 min; some at 5 min. TP and SRP: approximately at 2 weeks intervals Number of sites: 12
DOI: 10.6084/m9.figshare.21666215
title: Morphological variability and genetic marker stability of 16 monoclonal pennate diatom strains under medium-term culture

description: Monoclonal diatom strains are the basis for integrative taxonomical studies combining molecular and morphological data for better taxonomic resolution and identification. The identification of diatoms, based on morphological features of the frustule, is difficult due to the variability of characters within and amongst species. The longer the cultivation time, the more cell size is reduced during asexual reproduction. Many divisions of the cell complicate identification as morphological characters of the frustule change at different rates in different taxa and teratologies can develop. Morphological variability raises the question whether the investigated genetic markers are stable over the cultivation time span. Sixteen monoclonal pennate diatom strains, identified as 10 different species in six genera, were cultivated for up to 18 or 24 months. It was shown that molecular data for the 18S-V4, <i>rbc</i>L, and <i>psb</i>A markers were stable for the entire cultivation time of all taxa. Images of the valves of the strains were taken every six months and examined morphometrically. Depending on the time since the start of the cultures, the morphological features showed high variability, particularly in length and shape, whereas width and number of striae, costae or fibulae were more stable, depending on the taxon and strain. A limited time span and good culture conditions seem to be prerequisite to avoid the production of teratological frustules. The results of parallel cultures in a unique experimental design are compared to observations from the literature dealing with single strains or special cognitive interests.
DOI: 10.6084/m9.figshare.21666215.v1
title: Morphological variability and genetic marker stability of 16 monoclonal pennate diatom strains under medium-term culture

description: Monoclonal diatom strains are the basis for integrative taxonomical studies combining molecular and morphological data for better taxonomic resolution and identification. The identification of diatoms, based on morphological features of the frustule, is difficult due to the variability of characters within and amongst species. The longer the cultivation time, the more cell size is reduced during asexual reproduction. Many divisions of the cell complicate identification as morphological characters of the frustule change at different rates in different taxa and teratologies can develop. Morphological variability raises the question whether the investigated genetic markers are stable over the cultivation time span. Sixteen monoclonal pennate diatom strains, identified as 10 different species in six genera, were cultivated for up to 18 or 24 months. It was shown that molecular data for the 18S-V4, <i>rbc</i>L, and <i>psb</i>A markers were stable for the entire cultivation time of all taxa. Images of the valves of the strains were taken every six months and examined morphometrically. Depending on the time since the start of the cultures, the morphological features showed high variability, particularly in length and shape, whereas width and number of striae, costae or fibulae were more stable, depending on the taxon and strain. A limited time span and good culture conditions seem to be prerequisite to avoid the production of teratological frustules. The results of parallel cultures in a unique experimental design are compared to observations from the literature dealing with single strains or special cognitive interests.
DOI: 10.6084/m9.figshare.21357341
title: Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between <i>DPYD</i>-genotype variants and P-uracil concentrations

description: Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between <i>DPYD</i>-genotype variants and P-uracil concentrations
DOI: 10.6084/m9.figshare.21357341.v2
title: Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between <i>DPYD</i>-genotype variants and P-uracil concentrations

description: Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between <i>DPYD</i>-genotype variants and P-uracil concentrations
DOI: 10.6084/m9.figshare.21359444
title: The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis

description: The aim of this study was to evaluate the current role of local treatment in prostate cancer with a low metastatic burden (or oligometastatic) in relation to survival and safety. We performed a meta-analysis of studies published in the MEDLINE, EMBASE, and Cochrane databases until December 2021. Studies comparing local and nonlocal treatment in patients with metastatic prostate cancer were included. The risk of bias within studies was assessed using the Newcastle–Ottawa and Cochrane risk of bias tool. Oligo-metastasis was defined as low-volume metastasis with up to five lesions. The local treatment used was radical prostatectomy or external beam radiation therapy associated with systemic therapy (i.e., androgen deprivation therapy ± abiraterone, docetaxel, enzalutamide, or apalutamide). The endpoints evaluated were overall survival, cancer-specific survival, failure-free survival, and complication rates. Thirteen studies including 46,541 patients were included. The 5-year overall survival (16.0% vs. 6.5%, respectively; odds ratio (OR) 2.74; 95% confidence interval (CI), 2.18, 3.44; <i>I<sup>2</sup></i> = 0%; <i>p</i> &lt; .00001) and 3-year cancer-specific survival (48.2% vs. 26.3%, respectively; OR 1.87; 95% CI: 1.44, 2.44; <i>I<sup>2</sup></i> = 0%; <i>p</i> &lt; .00001) were higher in the local treatment group than that of the nonlocal treatment group. In addition, failure-free survival at 3 years was higher in the local treatment group than that of the nonlocal treatment group (40.5% vs. 28.4%, respectively; OR 1.72; 95% CI, 1.38, 2.14; <i>I<sup>2</sup></i> = 0%; <i>p</i> &lt; .00001). The low complication rate of Clavien–Dindo grade ≥3 indicated that local treatment is feasible and safe in this setting. Recent data have shown that local treatment combined with systematic therapy, might improve the overall, cancer-specific, and failure-free survivals of patients diagnosed with metastatic prostate cancer. Furthermore, local treatment is both feasible and safe. Further studies evaluating the quality of life of these patients are needed.
DOI: 10.6084/m9.figshare.21359444.v1
title: The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis

description: The aim of this study was to evaluate the current role of local treatment in prostate cancer with a low metastatic burden (or oligometastatic) in relation to survival and safety. We performed a meta-analysis of studies published in the MEDLINE, EMBASE, and Cochrane databases until December 2021. Studies comparing local and nonlocal treatment in patients with metastatic prostate cancer were included. The risk of bias within studies was assessed using the Newcastle–Ottawa and Cochrane risk of bias tool. Oligo-metastasis was defined as low-volume metastasis with up to five lesions. The local treatment used was radical prostatectomy or external beam radiation therapy associated with systemic therapy (i.e., androgen deprivation therapy ± abiraterone, docetaxel, enzalutamide, or apalutamide). The endpoints evaluated were overall survival, cancer-specific survival, failure-free survival, and complication rates. Thirteen studies including 46,541 patients were included. The 5-year overall survival (16.0% vs. 6.5%, respectively; odds ratio (OR) 2.74; 95% confidence interval (CI), 2.18, 3.44; <i>I<sup>2</sup></i> = 0%; <i>p</i> &lt; .00001) and 3-year cancer-specific survival (48.2% vs. 26.3%, respectively; OR 1.87; 95% CI: 1.44, 2.44; <i>I<sup>2</sup></i> = 0%; <i>p</i> &lt; .00001) were higher in the local treatment group than that of the nonlocal treatment group. In addition, failure-free survival at 3 years was higher in the local treatment group than that of the nonlocal treatment group (40.5% vs. 28.4%, respectively; OR 1.72; 95% CI, 1.38, 2.14; <i>I<sup>2</sup></i> = 0%; <i>p</i> &lt; .00001). The low complication rate of Clavien–Dindo grade ≥3 indicated that local treatment is feasible and safe in this setting. Recent data have shown that local treatment combined with systematic therapy, might improve the overall, cancer-specific, and failure-free survivals of patients diagnosed with metastatic prostate cancer. Furthermore, local treatment is both feasible and safe. Further studies evaluating the quality of life of these patients are needed.
DOI: 10.6084/m9.figshare.21545906
title: Socioeconomic inequality in cancer in the Nordic countries. A systematic review

description: Despite structural and cultural similarities across the Nordic countries, differences in cancer survival remain. With a focus on similarities and differences between the Nordic countries, we investigated the association between socioeconomic position (SEP) and stage at diagnosis, anticancer treatment and cancer survival to describe patterns, explore underlying mechanisms and identify knowledge gaps in the Nordic countries We conducted a systematic review of population based observational studies. A systematic search in PubMed, EMBASE and Medline up till May 2021 was performed, and titles, abstracts and full texts were screened for eligibility by two investigators independently. We extracted estimates of the association between SEP defined as education or income and cancer stage at diagnosis, received anticancer treatment or survival for adult patients with cancer in the Nordic countries. Further, we extracted information on study characteristics, confounding variables, cancer type and results in the available measurements with corresponding confidence intervals (CI) and/or p-values. Results were synthesized in forest plots. From the systematic literature search, we retrieved 3629 studies, which were screened for eligibility, and could include 98 studies for data extraction. Results showed a clear pattern across the Nordic countries of socioeconomic inequality in terms of advanced stage at diagnosis, less favorable treatment and lower cause-specific and overall survival among people with lower SEP, regardless of whether SEP was measured as education or income. Despite gaps in the literature, the consistency in results across cancer types, countries and cancer outcomes shows a clear pattern of systematic socioeconomic inequality in cancer stage, treatment and survival in the Nordic countries. Stage and anticancer treatment explain some, but not all of the observed inequality in overall and cause-specific survival. The need for further studies describing this association may therefore be limited, warranting next step research into interventions to reduce inequality in cancer outcomes. Prospero protocol no: CRD42020166296
DOI: 10.6084/m9.figshare.21545537
title: Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study

description: The real-world treatment and outcomes of patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer treated with ALK Tyrosine Kinase Inhibitor (TKI) drugs in Sweden is not well described. A retrospective population-based cohort study was conducted using Swedish national registers. All patients with a filled prescription for an ALK TKI between January 2012 and October 2020 were included. The sequencing of ALK TKI and duration of treatment (DOT) were described, and overall survival (OS) was estimated using the Kaplan–Meier method. Patients were stratified based on treatment with frontline chemotherapy, presence of CNS metastases prior to the first ALK TKI, and generation of ALK TKI agent. Among the total of 579 patients, 549 (95%) underwent a therapy sequence in line with current clinical practice with 204 (37%) patients receiving frontline chemotherapy. Single-line ALK TKI was given to 366 patients (crizotinib: 211; alectinib: 146; ceritinib: 9), whereas 128 patients received two different ALK TKI (frontline crizotinib: 100, alectinib: 24, ceritinib: 4); 40 patients received three lines and 15 patients four ALK TKI lines or more. With frontline chemotherapy, the mean (standard deviation) DOT was 1.07 (1.25) years for the entire TKI therapy sequence compared to 1.23 (1.28) years with frontline ALK TKI. The median (95% confidence interval) OS was 1.83 (1.48–2.13) years for the entire cohort, 1.44 (0.89–1.98) years for patients given frontline chemotherapy, and 2.02 (1.60–2.58) years for patients given frontline ALK TKI. This study provides a unique overview of the patient population treated with ALK TKI in Sweden and reveals the treatment patterns applied in real clinical practice. More research is needed when longer follow-up data are available for later-generation ALK TKI, to fully understand ALK TKI sequencing and its effect on patient survival in a real-world setting.
DOI: 10.6084/m9.figshare.21545537.v1
title: Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study

description: The real-world treatment and outcomes of patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer treated with ALK Tyrosine Kinase Inhibitor (TKI) drugs in Sweden is not well described. A retrospective population-based cohort study was conducted using Swedish national registers. All patients with a filled prescription for an ALK TKI between January 2012 and October 2020 were included. The sequencing of ALK TKI and duration of treatment (DOT) were described, and overall survival (OS) was estimated using the Kaplan–Meier method. Patients were stratified based on treatment with frontline chemotherapy, presence of CNS metastases prior to the first ALK TKI, and generation of ALK TKI agent. Among the total of 579 patients, 549 (95%) underwent a therapy sequence in line with current clinical practice with 204 (37%) patients receiving frontline chemotherapy. Single-line ALK TKI was given to 366 patients (crizotinib: 211; alectinib: 146; ceritinib: 9), whereas 128 patients received two different ALK TKI (frontline crizotinib: 100, alectinib: 24, ceritinib: 4); 40 patients received three lines and 15 patients four ALK TKI lines or more. With frontline chemotherapy, the mean (standard deviation) DOT was 1.07 (1.25) years for the entire TKI therapy sequence compared to 1.23 (1.28) years with frontline ALK TKI. The median (95% confidence interval) OS was 1.83 (1.48–2.13) years for the entire cohort, 1.44 (0.89–1.98) years for patients given frontline chemotherapy, and 2.02 (1.60–2.58) years for patients given frontline ALK TKI. This study provides a unique overview of the patient population treated with ALK TKI in Sweden and reveals the treatment patterns applied in real clinical practice. More research is needed when longer follow-up data are available for later-generation ALK TKI, to fully understand ALK TKI sequencing and its effect on patient survival in a real-world setting.
DOI: 10.6084/m9.figshare.21545906.v1
title: Socioeconomic inequality in cancer in the Nordic countries. A systematic review

description: Despite structural and cultural similarities across the Nordic countries, differences in cancer survival remain. With a focus on similarities and differences between the Nordic countries, we investigated the association between socioeconomic position (SEP) and stage at diagnosis, anticancer treatment and cancer survival to describe patterns, explore underlying mechanisms and identify knowledge gaps in the Nordic countries We conducted a systematic review of population based observational studies. A systematic search in PubMed, EMBASE and Medline up till May 2021 was performed, and titles, abstracts and full texts were screened for eligibility by two investigators independently. We extracted estimates of the association between SEP defined as education or income and cancer stage at diagnosis, received anticancer treatment or survival for adult patients with cancer in the Nordic countries. Further, we extracted information on study characteristics, confounding variables, cancer type and results in the available measurements with corresponding confidence intervals (CI) and/or p-values. Results were synthesized in forest plots. From the systematic literature search, we retrieved 3629 studies, which were screened for eligibility, and could include 98 studies for data extraction. Results showed a clear pattern across the Nordic countries of socioeconomic inequality in terms of advanced stage at diagnosis, less favorable treatment and lower cause-specific and overall survival among people with lower SEP, regardless of whether SEP was measured as education or income. Despite gaps in the literature, the consistency in results across cancer types, countries and cancer outcomes shows a clear pattern of systematic socioeconomic inequality in cancer stage, treatment and survival in the Nordic countries. Stage and anticancer treatment explain some, but not all of the observed inequality in overall and cause-specific survival. The need for further studies describing this association may therefore be limited, warranting next step research into interventions to reduce inequality in cancer outcomes. Prospero protocol no: CRD42020166296
DOI: 10.6084/m9.figshare.21334988
title: Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study

description: Data regarding characteristics, safety and survival outcomes of patients aged 80 or older treated with immune checkpoint inhibitors (ICI) in routine oncology practice are limited. We retrospectively collected data of patients aged 80 and older with advanced non-small cell lung cancer (NSCLC) or melanoma treated with anti-PD1, anti-PD-L1 or anti-CTLA-4 regardless of the treatment line, in 14 institutions, between January 2014 and June 2017. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan Meier method. Toxicity was assessed according to CTCAE 5.0. Multivariate analyses were performed with the Cox model. Eighty-two patients were included (36 with NSCLC, 45 with melanoma). Their median age was 82 years (range 80–93). Nivolumab and pembrolizumab were mainly used. In the NSCLC group, median PFS and OS were 2.3 months (95%CI 1.8–6.1) and 8.8 months (95%CI 5.5–18.1), respectively. In the melanoma group, median PFS and OS were 10.2 months (95%CI 4.5–20.0) and 24.5 months (95%CI 14.1–NR), respectively. The albumin level was found to be independently associated with a better OS in both groups. Grade 3–4 toxicities occurred in 15 patients (18.5%). One patient died from ICI-induced pulmonary toxicity. Our study findings suggest that treatment with ICI in elderly patients with NSCLC and melanoma has a risk-benefit ratio that supports its use. However, we report in this cohort that one in five patients has a grade 3–4 IRAEs leading to treatment discontinuation. Geriatric assessment prior to initiation of therapy and during therapy should be routine in patients aged 80 years and older.
DOI: 10.6084/m9.figshare.21334988.v1
title: Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study

description: Data regarding characteristics, safety and survival outcomes of patients aged 80 or older treated with immune checkpoint inhibitors (ICI) in routine oncology practice are limited. We retrospectively collected data of patients aged 80 and older with advanced non-small cell lung cancer (NSCLC) or melanoma treated with anti-PD1, anti-PD-L1 or anti-CTLA-4 regardless of the treatment line, in 14 institutions, between January 2014 and June 2017. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan Meier method. Toxicity was assessed according to CTCAE 5.0. Multivariate analyses were performed with the Cox model. Eighty-two patients were included (36 with NSCLC, 45 with melanoma). Their median age was 82 years (range 80–93). Nivolumab and pembrolizumab were mainly used. In the NSCLC group, median PFS and OS were 2.3 months (95%CI 1.8–6.1) and 8.8 months (95%CI 5.5–18.1), respectively. In the melanoma group, median PFS and OS were 10.2 months (95%CI 4.5–20.0) and 24.5 months (95%CI 14.1–NR), respectively. The albumin level was found to be independently associated with a better OS in both groups. Grade 3–4 toxicities occurred in 15 patients (18.5%). One patient died from ICI-induced pulmonary toxicity. Our study findings suggest that treatment with ICI in elderly patients with NSCLC and melanoma has a risk-benefit ratio that supports its use. However, we report in this cohort that one in five patients has a grade 3–4 IRAEs leading to treatment discontinuation. Geriatric assessment prior to initiation of therapy and during therapy should be routine in patients aged 80 years and older.